WGS (GeneDx Holdings) Shares Outstanding (EOP): 29.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WGS GeneDx Holdings Corp WGS
65 GF Score
Price $90.32
GF Value $73.77
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GeneDx Holdings Shares Outstanding (EOP)?

GeneDx Holdings WGS +3.30% 65 Shares Outstanding (EOP) is 29.8 Mil as of Jun. 2026. GuruFocus rates WGS with a GF Score™ of 65/100 and a GF Value™ of $73.77 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. GeneDx Holdings's shares outstanding for the quarter that ended in Jun. 2026 was 29.8 Mil.

GeneDx Holdings's quarterly shares outstanding increased from Mar. 2026 (29.7 Mil) to Jun. 2026 (29.8 Mil). It means GeneDx Holdings issued new shares from Mar. 2026 to Jun. 2026 .

GeneDx Holdings's annual shares outstanding increased from Dec. 2024 (28.0 Mil) to Dec. 2025 (29.2 Mil). It means GeneDx Holdings issued new shares from Dec. 2024 to Dec. 2025 .


GeneDx Holdings  (NAS:WGS) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


GeneDx Holdings Shares Outstanding (EOP) Related Terms


GeneDx Holdings Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for GeneDx Holdings's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeneDx Holdings Shares Outstanding (EOP) Chart

GeneDx Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial 7.35 11.77 25.98 28.02 29.25

GeneDx Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.71 28.89 29.25 29.67 29.80

WGS vs NEO, CDNA, PSNL: Shares Outstanding (EOP) Comparison

For the Diagnostics & Research subindustry, GeneDx Holdings's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneDx Holdings Shares Outstanding (EOP) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GeneDx Holdings's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where GeneDx Holdings's Shares Outstanding (EOP) falls into.


WGS
65GF Score
GeneDx Holdings Corp WGS
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GeneDx Holdings Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 29.8 Mil mean?
GeneDx Holdings (WGS) has a Shares Outstanding (EOP) of 29.8 Mil as of Jun. 2026. The total shares a company has outstanding, at period-end. View historical data on GeneDx Holdings and its competitors.
Is GeneDx Holdings' Shares Outstanding (EOP) too high?
GeneDx Holdings' current Shares Outstanding (EOP) is 29.8 Mil. Overall, GeneDx Holdings has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' Shares Outstanding (EOP) compare to NEO and CDNA?
GeneDx Holdings' Shares Outstanding (EOP) of 29.8 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Diagnostics & Research company?
A good Shares Outstanding (EOP) depends on the Medical Diagnostics & Research industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on GeneDx Holdings and its competitors. GeneDx Holdings's current Shares Outstanding (EOP) is 29.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Modestly Overvalued. The stock's GF Value™ is $73.77, compared to a current price of $90.32 — trading 22.4% above its estimated fair value. The current Shares Outstanding (EOP) is 29.8 Mil. GeneDx Holdings' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current Shares Outstanding (EOP) is 29.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GeneDx Holdings (WGS) Overvalued in 2026?

Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued. The current stock price of $90.32 is trading 22.4% above its estimated GF Value™ of $73.77. GuruFocus considers GeneDx Holdings to be Modestly Overvalued.

Key valuation signals for WGS:

  • Shares Outstanding (EOP): 29.8 Mil
  • GF Value™: $73.77 vs. price of $90.32 (22.4% above fair value)
  • GF Score™: 65/100 with 1 warning sign

No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GeneDx Holdings Business Description

Address 333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, USA, 06902
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
65GF Score

Get the complete analysis for WGS

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.32
Price
$73.77
GF Value